NDASUBLINGUALTABLET
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
ZUBSOLV (buprenorphine hydrochloride and naloxone hydrochloride) by Bridge Therapeutics is naloxone. First approved in 2013.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZUBSOLV is a sublingual tablet combining buprenorphine (a partial mu-opioid agonist) and naloxone (an opioid antagonist) for opioid use disorder maintenance treatment. Buprenorphine reduces cravings and withdrawal symptoms while naloxone discourages misuse via injection. The formulation leverages rapid dissolution technology to improve bioavailability and patient adherence.
$0.028BPart D
PeakStable
6.1 years to LOEProduct is at peak commercial maturity with modest Medicare spending and stable claim volume; brand teams focus on maintenance and managed-care penetration rather than expansion.
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
Started Nov 2013
33 enrolled
Opioid Dependence
Career Relevance
ZUBSOLV is a mature, stable franchise with modest headcount and limited new growth initiatives; roles focus on market maintenance, payer relations, and managed-care optimization. Career trajectory depends on your readiness to transition a product toward LOE or move to higher-growth assets post-2032.
Brand Manager
Worked on ZUBSOLV at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.